CT Private Equity Trust PLC

Quarterly Report 31 March 2025





Company Overview

The Company

CT Private Equity Trust PLC ("the Company") is an investment trust and its Ordinary Shares are traded on the Main Market of the London Stock Exchange.

Objective and Investment Policy

The Company's objective is to achieve long-term capital growth through investment in private equity assets, whilst providing shareholders with a predictable and above average level of dividend funded from a combination of the Company's revenue and realised capital profits.

Dividend Policy

The Company aims to pay quarterly dividends with an annual yield equivalent to not less than four per cent of the average of the published net asset values per Ordinary Share as at the end of each of its last four financial quarters prior to the announcement of the relevant quarterly dividend or, if higher, equal (in terms of pence per share) to the highest quarterly dividend previously paid. All quarterly dividends will be paid as interim dividends. The interim dividends payable in respect of the quarters ended 31 March, 30 June, 30 September and 31 December are expected to be paid in the following July, October, January and April respectively.

Management

The Company's investment manager, Columbia Threadneedle Investment Business Limited ("the Manager") is part of Columbia Threadneedle Investments. The ultimate parent company of Columbia Threadneedle Investments is Ameriprise Financial, Inc.

Net Assets as at 31 March 2025

£495.8 million.

Capital Structure as at 31 March 2025

71,502,938 Ordinary Shares of 1 pence, each entitled to one vote at a general meeting. In addition, the Company has 2,438,491 shares held in treasury.

Visit our website at www.ctprivateequitytrust.com

Financial Highlights

-0.8%	 NAV total return NAV total return per Ordinary Share for the three month period ended 31 March 2025 of -0.8 per cent.
-4.6%	 Share price total return Share price total return for the three month period ended 31 March 2025 of -4.6 per cent for the Ordinary Shares.
7.01p	 First Quarterly Dividend for 2025 Quarterly dividend of 7.01p per Ordinary Share payable on 31 July 2025.
6.1%	 Dividend Yield Dividend yield of 6.1 per cent based on the period end share price^{\$}.

^{\$} Calculated as dividends of 7.01p paid on 31 October 2024, 7.01p paid on 31 January 2025, 7.01p paid on 30 April 2025 and 7.01p payable on 31 July 2025 divided by the Company's share price of 459.00p as at 31 March 2025.



Long Term Outperformance

Summary of Performance

Total Returns for the Period*	Three months ended 31 March 2025	Year ended 31 December 2024	% change
Net asset value per Ordinary Share	-0.8%	+4.6%	
Ordinary Share price	-4.6%	+10.9%	
	As at 31 March 2025	As at 31 December 2024	% change
Capital Values			
Net assets (£'000)	495,803	504,829	-1.8%
Net asset value per Ordinary Share	693.40p	706.03p	-1.8%
Ordinary Share price	459.0p	488.0p	-5.9%
Discount to net asset value	33.8%	30.9%	
Income			
Revenue return after taxation (£'000)	324	1,652	
Revenue return per Ordinary Share	0.45p	2.30p	
Gearing†	15.4%	13.2%	
Future commitments (£'000)	182,394	193,012	

* Total return is the combined effect of any dividends paid, together with the rise or fall in the net asset value per Ordinary Share or share price. Any dividends are assumed to have been re-invested in either the Company at net asset value or share price.

+ Borrowings less cash ÷ total assets less current liabilities (excluding borrowings and cash).

Sources: Columbia Threadneedle Investment Business Limited and Refinitive Eikon

Movement in Net Asset Value for the quarter ended 31 March 2025



Manager's Review

Introduction

As at 31 March 2025 the net assets of the Company were £495.8 million giving a Net Asset Value per share of 693.40 pence which, taking account of the dividend of 7.01 pence paid on 31 January 2025, gives a total return for the quarter of -0.8%. This valuation is largely based on 31 December 2024 marks with only 3.5% of 31 March 2025 valuations included.

The share price total return for the quarter was -4.6%. The discount to NAV at quarter end was 33.8%, narrowing slightly to 30.9% at the time of writing.

At 31 March 2025 the Company had net debt of £90.4 million. The outstanding undrawn commitments were £182.4 million of which £28.7 million is to funds where the investment period has expired.

A dividend of 7.01 pence was paid on 30 April 2025. In accordance with the Company's dividend policy the next dividend will be 7.01 pence which will be paid on 31 July 2025 to shareholders on the register on 4 July 2025 with an exdividend date of 3 July 2025.

New Investments

Only one new investment was made in the quarter.

€2.1 million was invested in the Finnish IT services company Frendy. This is a co-investment alongside Procuritas, the long-established Nordic mid-market specialist. Frendy was formed by Procuritas in 2021 through the amalgamation of 10 companies with the aim of consolidating the fragmented IT services market in Finland. The original investment thesis has taken longer than expected and an opportunity arose for us to invest below the original entry price. Growth is now coming through driven by the transition to the cloud and strong demand for cyber-security. More companies have been added to the group and a growing proportion of revenues are on a recurring subscription basis. This is expected to be a shorter hold. CT Private Equity Trust holds 6.7% of the business.

The funds in the portfolio have added a number of interesting investments during the quarter. Software experts Axiom have called £1.8 million for Project Enola, a UK based investigation management and intelligence platform whose cloud based software is used by governments, police and investigation teams within corporates. SEP VI has called £1.4 million for two companies; Springtime, an Austrian accounts payable software company and Restrata a UK based critical event and business resilience software provider. Following the ubiquitous software theme, Volpi III has called £1.2 million for two companies; Bluestar, a Danish product life cycle software company and Telematrix, an Austrian provider of software for public transport. Verdane Edda invested £0.8 million across two platforms: Eversports a DACH focused software and sports facilities bookings platform; and Corlytics a regulatory intelligence and policy management software for financial services institutions and other regulated industries. In the consumer sector Piper Private Equity have called £0.6 million for Yard Sale Pizza, a chain of 14 shops in London which also delivers by e-bike and partners with 160 pubs and bars across London. The plan is to roll out the brand across London and other cities.

In North America Level 5 Fund II and Purpose Brands called $\pounds 0.8$ million for medical spa company Heyday. The company has 39 shops providing services such as dermaplaning and laser facials. TorQuest VI called $\pounds 1.0$ million for its first two investments; Mevotech is involved in the engineering, design and distribution of driveline, steering and suspension parts for the auto aftermarket; Athos is a funerary services company based in Quebec which is aiming to consolidate the fragmented Canadian market.

The total invested in new companies by way of co-investment and funds in the quarter was £15.7 million which was up 16% on Q4 2024 but down by 33% compared with the first quarter of 2024.

Realisations

Although the private equity market slowed somewhat as we entered 2025, there were a number of diverse exits or partial exits across the portfolio.

The largest inflow was of ± 3.1 million from our co-investment in electrical components company Sigma which has been recapitalised with a partial return to investors. The company had been in a sale process, but this will likely be paused as the impact of potential tariffs is assessed. So far, the additional costs have successfully been passed through to customers via price rises, however the longer term impact on demand in the company's end markets may take time to become clear.

Blue Point III returned £1.2 million (6.9x cost and 32% IRR) with the sale of industrial services contractor Sylvan, which provides design, installation and maintenance of industrial projects for clients in a range of sectors across North America. This company was held for seven years and built profits through derisking the supply chain by strategic acquisitions. Interestingly it was bought and sold for around 4.0x EBITDA.

Primary IV returned £1.1 million (3.6x cost and 21% IRR) with the sale of speciality signage company Metamark. MVM VI returned £1.1 million (4.0x cost and 216% IRR) from Gynesonics the developer of a minimally invasive medical device, Sonata, which is used for the treatment of uterine fibroids. Following a short hold of just 15 months the company was sold to Nasdaq listed Hologic. Vaaka III returned £0.9 million through a recapitalisation of Framery, the Finland based provider of sound proof office pods and workspaces.

There were a number of other exits bringing the total for the quarter to ± 10.3 million. This compares with ± 14.1 million in Q4 2024 and ± 16.1 million in Q1 2024.

Manager's Review (continued)

Valuation Movements

There were very few significant movements in valuation in the first quarter. Only 3.5% of the valuations were based on March 2025 marks with the remainder based on December 2024 valuations. This is not unusual as the valuation is compiled only a few weeks after the full year reports from our investments have been finalised.

There were two helpful positives from US funds Graycliff IV and Blue Point III which were up by £0.6 million and £0.4 million respectively, as a result of recent exits. On the negative side Italian focused fund Wise Equity VI was down by £0.7 million due to some pressures in the portfolio from the weaker economic background. It is still quite early in the life of the fund.

Financing

At 31 March 2025 the Company had net debt of £90.4 million. This is up from £76.5 million at 31 December 2024 but on a twelve-month basis is down by around £9 million. In the quarter total realisations were below the total of new investments by £5.4 million. The level of gearing at 31 March 2025 was 15.4%. The Company retains around £55 million of headroom in its borrowing facility and the current debt level is eminently manageable. The small dip in the first quarter's NAV is normal and in line with previous years.

Outlook

The private equity sector, in common with all other investment asset classes, has monitored the economic announcements from the US in recent weeks. Specifically attention has been paid to the proposed tariffs which have broken the long-standing paradigm that largely free trade is a desirable economic objective likely to bring increased prosperity to the greatest number of people. Apart from the adverse economic consequences, which are widely expected to follow, subsequent changes in the proposed tariffs have engendered an unusual degree of uncertainty. Even though many private equity backed companies are not directly affected by US trade tariffs, this kind of economic intervention and high level of uncertainty is not good for deal-making. Unsurprisingly we have seen some planned exits being postponed as buyers pause to consider whether the target company will be affected or not. Uncertainty also influences fund investors who are considering committing long term capital to the asset class with the current situation providing the perfect justification for holding off on new commitments. Most private equity investors are attracted to companies and sectors with clear long-term growth drivers provided that investment can be made at a price which adequately reflects the risks of the planned growth being achieved. There are likely to be changes in the value of private companies with some winners as well as losers and other factors such as flight to quality coming into play over the coming months.

Private equity is one of the most deliberative of investment management disciplines with investors not committing capital until they are in full possession of the facts and have made a full assessment of the future of a company. This research usually takes several months or even years before an investment is made. Once an investment has been made it cannot be easily reversed if the market or the economic environment changes dramatically. Private equity does however possess the ability to work with the management of investee companies to tackle any challenges and in adverse or uncertain periods the first priority of private equity managers is to support and assist their existing portfolio. Your portfolio is unusually diverse covering hundreds of companies internationally with exposure to multiple sectors and their associated economic trends and drivers. This diversification has proven to be a strength historically and it will doubtless prove to be of benefit now in protecting and building shareholder value. From here we expect that after a period of assessment the improvement in private equity activity levels which we saw during 2024 will resume.

Hamish Mair Investment Manager

Columbia Threadneedle Investment Business Limited

Co-investment Case Study– Amethyst Radiotherapy



Background

Founded in 2010, Amethyst Radiotherapy is a leading pan-European operator of radiotherapy clinics, offering comprehensive oncology treatments. At the time of the Company's investment, it served more than 11,000 patients annually at nine radiotherapy clinics in France, Poland, Romania and Italy. The business had pursued a joint greenfield and M&A strategy, building out organically in Eastern Europe and acquiring and updating sites in Western Europe.

CT Private Equity Trust PLC backed The Rohatyn Group ("TRG"), a Central and Eastern European focused buyout investor with whom it has invested on several occasions, including the successful Pet Network investment (4.2x cost, 54% IRR).

The deal completed at an enterprise value of €115 million, equivalent to 9.6x 2018 adjusted EBITDA of £12.0 million. CT Private Equity was the lead investor in the LP syndicate, investing a total of £20 million (CT Private Equity Trust: £4.5 million).

Investment Rationale and Performance

- Clear value proposition, but market undersupply radiotherapy is suited to the treatment of many types of cancer, and it is 3-5x more cost effective than chemotherapy. However, despite radiotherapy being clinically recommended in c.50% of cancer cases, treatment rates in Europe are 10-30% below this level due to insufficient availability of the latest radiotherapy treatment technologies. This supply-demand imbalance is particularly acute in Eastern Europe.
- Number two Pan-European player with few companies of scale at the time of investment, Amethyst was the second largest pan-European player, with well invested centres (including state-of-the-art linac technology) and a strong track record of M&A. It was an excellent platform to consolidate the market through M&A to acquire and update existing centres and by building greenfield centres in areas of undersupply.
- Higher barriers to entry excellent reputation in highly regulated industry with requirement for medical and nuclear licences.
- Attractive financial profile and performance since being founded the company had grown revenues to €45 million (2018A) in seven years, with strong EBITDA growth in 2017 and 2018 at 30%+ CAGR. It had high EBITDA margins over 25%, reflecting the high value service it provides in the healthcare sector.

During CT Private Equity Trust's ownership period, the company expanded the number of centres from 8 to 19 across France, Poland, Romania, the UK, Italy and Austria. Amethyst has increased the number of patients served by nearly five times, from 11,000 patients per annum to over 50,000, significantly enhancing access to life saving treatment.

Revenues grew from \notin 53.9 million in 2019, to \notin 139.9 million and EBITDA grew from \notin 15.9 million to \notin 31.5 million (pre IFRS 16) in the same period. Recent performance has been strong, with revenue growth of 39% in 2024 whilst maintaining EBITDA margin at 23%. Transition from the co-founders to an experienced and professional management team was also completed, with a new CEO and CFO joining in April 2023, augmenting the experienced country management teams in each market.

Exit

In April 2025, the founders and TRG agreed to sell the business to Fremman Capital, a pan-European private equity fund. The sale is subject to regulatory approval and is expected to complete in Q3 2025.



Portfolio Summary

Portfolio Distribution As at 31 March 2025	% of Total 31 March 2025	% of Total 31 December 2024
Buyout Funds - Pan European*	12.2	11.6
Buyout Funds - UK	19.5	19.2
Buyout Funds - Continental Europe ~	15.3	15.5
Secondary Funds	-	_
Private Equity Funds - USA	4.6	4.4
Private Equity Funds - Global	2.6	2.7
Venture Capital Funds	4.4	4.5
Direct Investments/Co-investments	41.4	42.1
	100.0	100.0

* Europe including the UK.

 \sim Europe excluding the UK.

Ten Largest Individual Holdings As at 31 March 2025	Total Valuation £'000	% of Total Portfolio
Inflexion Strategic Partners	19,296	3.3
Weird Fish	14,845	2.5
Sigma	12,521	2.1
August Equity Partners V	12,129	2.1
TWMA	12,087	2.1
Utimaco	10,791	1.8
San Siro	10,588	1.8
Aurora Payment Solutions	9,699	1.6
Inflexion Supplemental V	9,697	1.6
Stirling Square Capital II	9,601	1.6
	121,254	20.5

*Sold following the period end.

Portfolio Holdings

Appoint Perturbation III monors Entropy Perturbation III monors Perturbation IIII monors Perturbation IIII monors	Investment	Geographic Focus	Total Valuation £'000	% of Total Portfolio
Sick Europen Cashed PattersEar of yearSolar of year <td>Stirling Square Capital II</td> <td></td> <td></td> <td>1.6</td>	Stirling Square Capital II			1.6
Agouth Image by the property of the pr				1.6 1.5
Wail II Nother Lucies 3.15.3 0.6.5 Algents 2006 Fare Nother Lucies 3.15.2 0.0.5 Algents 2006 Fare Nother Lucies 3.15.2 0.0.5 Algents 2007 Fare Nother Lucies 3.16.2 0.0.5 Algents 2007 Fare Nother Lucies 3.16.2 0.0.5 Algents 2007 Fare Nother Lucies 3.16.2 0.0.5 Algents 2007 Fare Nother Lucies 1.0.20 0.0.5 Algents 2007 Fare 1.0.20	Apposite Healthcare II	Europe	8,457	1.4
Sunn III Sunn III Multe 201 Provide Multe 201 Provide 	Volpi III			0.6
Alleis 2015 Fud Nuthern Einige 3.033 0.53 Alleis 2015 Fud Western Finige 2.310 0.40 Wissel Win Call 1.400 0.40 Wissel Win Call 1.400 0.40 Wissel Win Europe 1.400 0.40 Wissel Win Wissel Win 1.400 0.40 Wissel Win Wissel Win 1.400 0.40 Wissel Win Wissel Win 1.400 0.400 Wissel Win	Summa III	Northern Europe	3,309	0.6
Magnet purch Setter 1				0.6
Net-Encloy Lably 2.715 0.40 WACEN COD II Northen Lurge 1.989 0.03 KALI Europe 11.989 0.03 KALI Europe 11.989 0.03 KALI Europe 11.989 0.03 KALI Europe 11.989 0.03 KALI Water Coll 1.989 0.03 KALI Water Coll 1.989 0.03 KALI Water Coll 1.989 0.03 KALI Water Coll Water Coll 0.00 Mater Coll Water Coll 1.990 1.990 1.990 Mater Coll Table Coll 1.990	Magnesium Capital 1	Europe	2,512	0.4
MED Platform II Calcal at 1.45 0.4 A Worther During at 1.450 ABC MED BU Calcal At 1.470 ABC MED BU CALCAL AT 1.470<				
Kin II Enrore 1.558 0.50 Applies 2020 Fund Eurose 1.258 0.20 TIT C Explicit Western Eurose 1.258 0.20 Applies 2020 Fund Western Eurose 1.258 0.20 Applies 2020 Fund Western Eurose 1.258 0.20 Applies 2020 Fund Eurose 1.258 0.20 Applies 2020 Fund Eurose 1.258 0.20 TIT E Explicit Fundes Vestern Eurose 1.25 0.20 TIT E Explicit Fundes Vestern Eurose 1.25 0.20 TIT E Explicit Fundes Vestern Eurose 1.2	MED Platform II	Global	2,145	0.4
ARCHMENT MU Chead 1.470 0.50 TRO IL AND IL Western Furne 1.470 0.50 0.20 TRO IL AND IL Western Furne 1.055 0.20 ARDMENT AND IL Western Furne 1.055 0.20 Entropic Fund V Europe 1.20 0.20 Find Hour Fund - NE Europe 1.20 0.20 Find Hour Fund - NE Funde - NE 1.20 0.20 Find Hour Fund - NE Funde - NE 1.20 0.20 Autor Fund - NE Under Kingtom 1.20 0.20 1.21 Autor Fund - NE Under Kingtom 1.20 0.20 1.21 Autor Fund - NE Under Kingtom 1.20 0.20 1.21 Autor Fund - NE Under Kingtom 1.20 0.20 1.21 Autor Fund - NE Under Kingtom 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20				
TBC CapBit II Weatern Lurope 1.23 0.2 Applite Jong CAP HIP Weatern Lurope 1.23 0.2 Applite Jong CAP HIP Lurope 1.3 - Total Form France Lurope 1.2 - Michaon Intergram Lurope 1.2 - Michaon Intergram Under Argent 1.2 1.2 Michaon Intergram	ARCHIMED MED III	Global	1,470	0.3
TDR II Amment Fund Western Europe 1.069 0.3 Untextor Europe F.3 Total Byout Funds - UK Europe F.3 Brows Forder W Untext August Brows Forder W Untext August				
Applies Europe Part and Section Fund Y Europe Fund Section Fund Y 120	TDR II Annex Fund	Western Europe	1,059	0.2
Inflexion Find Twi Europe Find Find Brower Funds - VK United Knightom 9.995 3.2 Brower Funds - VK United Knightom 9.995 3.2 Indexion Support Funds - VK United Knightom 9.095 3.2 Indexion Support Funds - VK United Knightom 9.005 3.2 Indexion Support Funds - VK United Knightom 9.005 3.2 Adem 3 Capital Partners I United Knightom 6.065 1.1 Adem 3 Capital Partners I United Knightom 6.066 1.0 PF Fund II United Knightom 4.066 0.06 Adem 3 Capital Partners I United Knightom 4.066 0.06 Nagari Eduly M United Knightom 4.067 0.07 Carran Environmental I United Knightom 4.067 0.07 Stephen Capital II United Knightom 3.084 0.7 0.7 Pier Fund II United Knightom 3.084 0.7 0.7 0.7 Pier Fund Eduly M United Knightom 3.084				
Buyout Printers V United Kingdom 15/280 3.3 August Buyin Printers V United Kingdom 16/280 3.3 August Buyin Printers V United Kingdom 16/280 2.1 August Buyin Printers V United Kingdom 6.799 1.1 August Buyin Printers V United Kingdom 6.799 1.1 August Buyin Printers V United Kingdom 6.799 1.1 Kindexon Buyout Fund V United Kingdom 6.799 1.1 Kindexon Buyout Fund V United Kingdom 6.060 0.8 Kindexon Buyout Fund V United Kingdom 6.060 0.8 Kindexon Buyout Fund V United Kingdom 4.395 0.7 Kindexon Buyout Fund V United Kingdom 4.395 0.7 Kindexon Stanguet Buyout United Kingdom 3.822 0.7 Filer Printers Kingdom 4.395 0.7 0.7 Kindexon Stanguet Buyout United Kingdom 3.222 0.7 Filer Printe Exalt VI United Kingdom 3.222 0.7 Kin	Inflexion Enterprise Fund VI			_
Infexiors Strategic Partners United Ringtom 19.269 3.3 Atom 1 United Ringtom 6.769 1.1 Atom 1 United Ringtom 6.769 1.1 Indexion Byout Fard V United Ringtom 6.769 1.1 Indexion Byout Fard VI United Ringtom 6.769 1.1 Indexion Byout Fard VI United Ringtom 6.769 1.1 Indexion Byout Fard VI United Ringtom 6.769 1.0 Ref Fard II United Ringtom 4.560 0.0 Ref Fard II United Ringtom 4.560 0.0 Carran Extremental II United Ringtom 4.560 0.0 Carran Extremental II United Ringtom 4.500 0.0 Ref Fard II United Ringtom 3.262 0.0 Carran Extremental II United Ringtom 3.262 0.0 Ref Fard III United Ringtom 3.262 0.0 Carran Extremental III United Ringtom 1.480 0.0 Ref Fard III United Ringtom 1.480 <td>Total Buyout Funds – Pan European</td> <td></td> <td>71,859</td> <td>12.2</td>	Total Buyout Funds – Pan European		71,859	12.2
August Equity Pintners V United Kingdom 12,129 21,1 Infeaton Buyout Fund V United Kingdom 6,765 11 Augurt Capable Fund V United Kingdom 6,765 11 Augurt Capable Fund V United Kingdom 6,765 11 Augurt Capable Fund V United Kingdom 6,765 11 PEF Fund II United Kingdom 4,365 0.06 FEF Fund II United Kingdom 4,365 0.07 Carran Environmental II United Kingdom 4,365 0.07 Fer Fund II United Kingdom 4,362 0.07 August Exaty Nit United Kingdom 4,362 0.07 Per Prote Trans Environmental II United Kingdom 4,322 0.07 Per Prote Trans Environmental II United Kingdom 3,384 0.07 Per Prote Trans Environmental II United Kingdom 3,384 0.07 Master Exaty Nit United Kingdom 1,453 0.07 Master Exaty Nit United Kingdom 1,453 0.07 Master Exat	Buyout Funds - UK		40.000	
Infeston Supplemental V United Kingdom 6.697 1.6 Apan 1 United Kingdom 6.759 1.1 Apany Capitél Partners I United Kingdom 6.759 1.0 Apany Capitél Partners I United Kingdom 6.769 1.0 Mapar Capitél Partners I United Kingdom 4.669 0.0 PE Find I United Kingdom 4.669 0.0 Carace Explain United Kingdom 4.669 0.0 Carace Explain United Kingdom 4.660 0.0 Carace Explain United Kingdom 4.607 0.0 Carace Explain United Kingdom 4.607 0.0 Carace Explain United Kingdom 4.007 0.07 Pare Anate Explain United Kingdom 3.607 0.0 Kaster Capital United Kingdom 3.607 0.0 Carace Explain United Kingdom 3.607 0.0 Carace Explain United Kingdom 3.607 0.0 Carace Explain United Kingdom 3.607		United Kingdom United Kingdom	19,296 12,129	3.3 2.1
Infeston Boyout Fund Y United Knigdom 6.755 1.1 ApplY Capabil Printers I United Knigdom 6.756 1.1 PFE Fund II United Knigdom 6.766 0.8 PFE Fund II United Knigdom 4.866 0.8 Koster Capabil II United Knigdom 4.866 0.8 Koster Capabil II United Knigdom 4.207 0.7 Inflexon Filter String Capabil II United Knigdom 4.055 0.7 Inflexon Filter String Capabil II United Knigdom 4.055 0.7 Inflexon Filter String Capabil II United Knigdom 4.055 0.7 Inflexon Filter String Capabil II United Knigdom 3.067 0.5 Inflexon Filter String Capabil II United Knigdom 1.443 0.2 Inflexon Filter String Capabil II United Knigdom 1.444 0.2 Inflexon Filter String Capabil II United Knigdom 3.16 0.1 Inflexon Filter String Capabil II United Knigdom 3.17 0.1 Inflexon Filter String Capabil II United Knigdom	Inflexion Supplemental V	United Kingdom	9,697	1.6
Anay. Capital Partners I United Kingdom 6.456 1.1 Misea on Byour Than V United Kingdom 4.645 1.0 PEF Fund I United Kingdom 4.646 0.0 Meater Capital I United Kingdom 4.647 0.0 Meater Capital I United Kingdom 4.647 0.0 Meater Capital II United Kingdom 4.057 0.0 Meater Capital II United Kingdom 4.057 0.0 Per Private Eauly VII United Kingdom 3.022 0.0 Per Private Eauly VII United Kingdom 2.257 0.0 Inteison Byour Fund W United Kingdom 2.151 0.0 Inteison Eauly MI United Kingdom 2.151 0.0 Inteison Eauly MI United Kingdom 2.151 0.0 Inteison Eauly Kingdom United Kingdom 1.136 0.0 Inteison Eauly Kingdom 1.246 0.0 0.0 0.0 Inteison Eauly Kingdom 1.246 0.0 0.0 0.0 0.0 Int				
PFE Find II Under Kingborn 4.869 0.8 Kester Capital II Under Kingborn 4.869 0.8 Kester Capital II Under Kingborn 4.285 0.7 Corran Environmental II Under Kingborn 4.285 0.7 Inflexion Partnersing Capital II Under Kingborn 4.282 0.7 Pipe Protecting Capital II Under Kingborn 4.282 0.7 Kester Capital II Under Kingborn 4.282 0.7 Kester Capital II Under Kingborn 3.84 0.7 Kester Capital II Under Kingborn 1.449 0.5 Kester Capital II Under Kingborn 1.449 0.2 Inflexion Enterprise Fund V Under Kingborn 1.449 0.2 Inflexion Enterprise Fund V Under Kingborn 1.449 0.2 Kingborn End V Under Kingborn 1.449 0.2 Kingborn End V Under Kingborn 1.487 0.4 Kingborn End V Under Kingborn 1.487 0.4 Kingborn End V Under K	Apiary Capital Partners I		6,456	1.1
PE Find II Unted Kingdom 4.866 0.8 Quiste Equity Photers V Unted Kingdom 4.867 0.8 Corran Environmental II Unted Kingdom 4.207 0.7 Intesion Patterstrok Capital II Unted Kingdom 4.207 0.7 Intesion Patterstrok Capital II Unted Kingdom 3.922 0.7 Kester Capital II Unted Kingdom 3.922 0.7 Kester Capital II Unted Kingdom 3.922 0.7 Intesion Enterpreservation Unted Kingdom 3.922 0.6 Intesion Enterpreservation Unted Kingdom 2.145 0.6 Intesion Enterpreservation Unted Kingdom 1.454 0.2 Intesion Enterpreservation Unted Kingdom 1.432 0.2 Intesion Enterpreservation Unted Kingdom 1.6 0.2 0.1 Intesion Enterpreservation Unted Kingdom 1.6 0.2 0.1 Intesion Enterpreservation Unted Kingdom 1.6 0.2 0.1 Intesion Enterpreservation Unted Kingdom				
Kesier Capital II Untick Krigdom 4.395 0.7. Orara Ehvironmental II unal Unick Krigdom 4.395 0.7. Piper Private Equity VI Unick Krigdom 3.922 0.7. Piper Private Equity VI Unick Krigdom 3.922 0.7. Piper Private Equity VI Unick Krigdom 3.922 0.7. Rester Capital II Unick Krigdom 3.922 0.7. Rester Capital II Unick Krigdom 3.067 0.5. Intexion Enrotic Fund V Unick Krigdom 3.067 0.5. Intexion Enrotic Fund V Unick Krigdom 1.443 0.2. Intexion Enrotic Fund V Unick Krigdom 1.434 0.2. Intexion Enrotic Fund V Unick Krigdom 3.77 0.1. Prior Oracit Equity V Unick Krigdom 3.77 0.1. Prior Oracit Equity V Unick Krigdom 3.77 0.1. Prior Prote Equity V Unick Krigdom 3.77 0.1. Prior Prote Equity V Unick Krigdom 3.77 0.1. Dender Broo	FPE Fund II			0.8
Coran Environmental II United Kingdom 4.207 0.7.7 Piper Private Equity VI United Kingdom 3.224 0.7 Piper Private Equity VI United Kingdom 3.224 0.7 Rester Capital III United Kingdom 3.224 0.7 Kester Capital III United Kingdom 3.225 0.4 Inflexion Enterprise Fund V United Kingdom 2.225 0.4 Inflexion Enterprise Fund V United Kingdom 1.434 0.0 RD Private Equity Fund III United Kingdom 1.66 0.0 RD Private Equity Fund III United Kingdom 1.66 0.0 Piper Private Equity Fund III United Kingdom 1.66 0.0 Drest Private Equity Fund III United Kingdom 1.66 0.0 Drest Private Equity Fund IIII United Kingdom 1.66	August Equity Partners IV			0.8
inflexion Partnership Capital II United Kingdom 4.055 0.7 Prepr Private Equity WI United Kingdom 3.022 0.7 Mester Capital II United Kingdom 3.067 0.05 Inflexion Equity Hu United Kingdom 3.067 0.05 Inflexion Equity Hu United Kingdom 2.118 0.4 Inflexion Equity Fund IV United Kingdom 1.434 0.2 Inflexion Equity Fund II United Kingdom 1.434 0.2 Inflexion Equity Fund II United Kingdom 1.434 0.2 Inflexion Equity Fund III United Kingdom 1.6 0.2 Private Equity Fund III United Kingdom 1.6 0.2 0.2 Inflexion Equity Fund II United Kingdom 1.6 0.2				
Piper Private Equity Vi United Kingdom 3.884 0.7. Kester Capital United Kingdom 2.016 0.05 Inflexion Enterprise Fund V United Kingdom 2.116 0.04 Inflexion Enterprise Fund V United Kingdom 1.4489 0.2 Inflexion Enterprise Fund V United Kingdom 1.434 0.2 Inflexion Enterprise Fund V United Kingdom 1.434 0.2 Inflexion Enterprise Fund V United Kingdom 1.434 0.2 Inflexion Enterprise Fund V United Kingdom 1.63 - Inflexion Experimental IV United Kingdom 163 - Primary Capital 2013 United Kingdom 163 - Incadi Buyout Fund II Danedin Buyout Fund II 5 - Danedin Buyout Fund II Polarnd 6.429 1.1 Avaiton MBO Fund III Banter Equity 3 1.0 - Avaiton MBO Fund III Danedin Ganta 3 1.0 - Danedin Buyout Fund II Danedin Ganta 3 1.0 -	Inflexion Partnership Capital II	United Kingdom	4,055	0.7
Kester Capital II United Kingdom 3.067 0.53 Inflexion Buyori Fund IV United Kingdom 2.226 0.4 Inflexion Buyori Fund IV United Kingdom 2.226 0.4 Inflexion Enterprise Hail IV United Kingdom 2.226 0.4 Inflexion Enterprise Fund IV United Kingdom 1.266 0.2 Inflexion Enterprise Fund IV United Kingdom 3.261 0.1 Inflexion Enterprise Fund IV United Kingdom 3.261 0.1 Porter Equity Fund II United Kingdom 3.01 0.1 Porter Equity V United Kingdom 1.09 - Agues Equity V United Kingdom 1.09 - Agues Equity V United Kingdom 1.0 - Daneelin Buyor Fund II United Kingdom 1.4 - Daneelin Buyor Fund II United Kingdom 1.4 - Daneelin Buyor Fund II United Kingdom 1.4 - - Daneelin Buyor Fund II United Kingdom 1.4 - -				
Inflexion Erierprise Fund V United Kingdom 2.116 0.4 Inflexion Enterprise Fund II United Kingdom 1.443 0.2 Inflexion Enterprise Fund II United Kingdom 1.663 0.2 Inflexion Enterprise Fund II United Kingdom 1.663 0.2 RD Private Equily Fund II United Kingdom 377 0.1 Horizon Capital 2013 United Kingdom 311 0.1 August Equily Partners VI United Kingdom 91 - GCP Europe II United Kingdom 91 - Inflexion Supfaremental V United Kingdom 91 - GCP Europe II United Kingdom 91 - Inflexion Supfaremental V United Kingdom 91 - Core Decision United Kingdom 91 - Inflexion Supfaremental V United Kingdom 91 - Core Decision United Kingdom 91 - Inflexion Experimental V United Kingdom 91 - Core Decision United Kingdom	Kester Capital III	United Kingdom	3,067	0.5
Inflexion Supplemental IV United Kingdom 1,449 0.2 Inflexion Entrynsip Capital I United Kingdom 1,269 0.2 Inflexion Entrynsip Capital I United Kingdom 377 0.1 Primary Capital IV United Kingdom 321 0.1 Primary Capital IV United Kingdom 321 0.1 August Equity Partners VI United Kingdom 163				0.4
Inflexion Erkerprise Fund IV United Kingdom 1.434 0.2 RDP Private Equity Fund III United Kingdom 1.266 0.2 RDP Private Equity Fund III United Kingdom 4.67 0.1 Piner Notabie IN United Kingdom 4.67 0.1 Piner Notabie Equity V United Kingdom 163 - August Equity Parters VI United Kingdom 19 - GCP Europe II United Kingdom 19 - Total Exourb Ends Inted Kingdom 19 - August Equity Parters VI United Kingdom 19 - August Equity Parters VI United Kingdom 19 - August Equity Aug				0.4
RJD Private Equity Fund III United Kingdom 467 0.1. Prinzery Capital IV United Kingdom 321 0.1. Prinzery Capital IV United Kingdom 321 0.1. August Equity V United Kingdom 101	Inflexion Enterprise Fund IV			0.2
Horizon Capital 2013 United Kingdom 377 0.1. Piner Provate Equity V United Kingdom 123				
Piper Fiveire Equity V United Kingdom 163 GCP Europe II United Kingdom 91 Duncin Buyout Fund I United Kingdom 91 Total Buyout Funds - UK 114,822 13.5 Buyout Funds - Octiniental Europe Italy 8.467 1.4 Alante Equity 3 Poland 6.429 1.1 DBAC VII Poland 5.246 0.9 Valiante Supti Funds - UK Benelux 5.246 0.9 Valiante Supti Funds - UK Benelux 5.246 0.9 Valiante Supti Funds - UK Benelux 5.246 0.9 Valiante IIC V OACH 5.843 1.0 DBAC VII Benelux 5.040 0.8 Wortane Edda Nordic 4.508 0.8 Mortefiore V Bante Supti Funds - UK 0.8 0.4 Corpfin V Pocurtas VI DACH 4.185 0.7 Corpfin V Pocurtas VI Nordic 3.773 0.66 Chacue	Horizon Capital 2013	United Kingdom	377	0.1
August Equity Partners VI United Kingdom 109 Dunedin Buyout Fund II United Kingdom 91 Total Buyout Funds - UK 114.832 19.5 Buyout Funds - Continental Europe Italy 8.467 1.4 Availen MBO Fund III Poland 6.429 1.1 DBAG VII DACH 5.843 1.0 Benei K 5.296 0.9 9.848 Vaaka III Benei K 5.296 0.9 Vaaka III Constrain Cons				0.1
Dunedin Buyout Fund II United Kingdom 5	August Equity Partners VI	United Kingdom	109	-
Total Buyout Funds – UK 114,832 19,5 Buyout Funds – Continental Europe Italy 8,467 1.4 Availon MBO Fund III Poland 6,423 1.1 DBAG VII Poland 6,423 1.1 DBAG VIII Buck VIIII Poland 6,423 1.1 DBAG VIII Buck VIIIII Poland 6,423 1.1 Vaala II Buck VIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII				_
Aliant Equity 3 taty 8,467 1.4 Avalon MBO rund III Poland 6,429 1.1 DBAG VII DACH 5,843 1.0 Bencis V Benelux 5,296 0.9 Vaaka III DACH 4,710 0.8 Capvis III CV DACH 4,710 0.8 Werdane Edda Nordic 4,509 0.8 Kontefiore V France 4,303 0.7 DBAG VIII DACH 4,185 0.7 Orpfin V Spalin 4,135 0.7 Procuritas VI Nordic 3,773 0.6 ARX CEE IV France 3,773 0.6 Chequers Capital XVI Nordic 2,595 0.4 Tatiai Porticitas VI Nordic 2,595 0.4 Tatiai Porticitas Capital IV Italia Porticitas 1.143 0.3 Varica IV Spalin 1,145 0.3 Varica IV Spalin 1,145 0.3 Surma I Nordic 1,513 0.3 Surma I Nordic	Total Buyout Funds – UK			19.5
Avalion MBO [†] rund III Poland [*] 6.4.29 1.1 BBAG VII DACH 5.843 1.0 Bencis V Benelux 5.2.96 0.9 Vaaka III Finland 5.008 0.8 Capvis III CV DACH 4.7.10 0.88 Verdane Edda Nordic 4.509 0.8 Montefiore V DACH 4.136 0.7 Corpfin V DACH 4.136 0.7 Procuritas VI Nordic 3.877 0.6 Chequers Capital XVII Rance 2.302 0.6 Chequers Capital XVII Nordic 3.877 0.6 Chequers Capital XVII Eastern Europe 2.980 0.5 Procuritas Capital IV Nordic 2.587 0.4 Aurica IV Spain 2.188 0.4 Capital IV Nordic 1.513 0.3 Surma I Spain 2.188 0.3 Surma I Nordic 1.513 0.3 Surma I </td <td>Buyout Funds – Continental Europe</td> <td></td> <td></td> <td></td>	Buyout Funds – Continental Europe			
DBAG VII DACH 5.843 1.0 Bencis V Benelux 5.008 0.9 Vaaka III Finland 5.008 0.8 Capvis III CV DACH 4.7.10 0.8 Verdane Edda Nordic 4.509 0.8 Wontefiore V France 4.303 0.7 DBAG VIII DACH 4.185 0.7 DRAG VIII Nordic 3.874 0.7 Procurtas VI Nordic 3.874 0.7 Procurtas VI Nordic 3.720 0.6 Chequers Capital XVI France 3.720 0.6 Natk CEE IV Fastern Europe 2.980 0.5 Procurtas VI Nordic 2.555 0.4 Variaa IV Auria V 2.517 0.4 Variaa IV Sapiai 2.138 0.4 Cayis IV Nordic 1.513 0.3 Summa I Sapiai 1.145 0.23 Summa I Nordic 1.				
Vaaka III Finland 5.008 0.83 Cayvis III CV DACH 4,710 0.83 Verdane Edda Nordic 4,509 0.83 Montefiore V France 4,303 0.7 DBAG VIII DACH 4,185 0.7 Oropfin V Spain 4,136 0.7 Procurtas VI Nordic 3,874 0.7 Procurtas VI Nordic 3,874 0.7 Procurtas VI Nordic 2,595 0.6 Procurtas Capital XVI Nordic 2,595 0.4 Italia Portfolio Nordic 2,595 0.4 Vaaka IV Nordic 2,595 0.4 Aurica IV Spain 2,138 0.4 Aurica IV Spain 2,138 0.4 Summa I DACH 1,816 0.3 Summa I Spain 1,145 0.2 Corpfin Capital Fund IV Spain 1,145 0.2 DBAG Fund VI DACH	DBAG VII	DACH	5,843	1.0
Capvis III CV DACH 4,710 0.8 Wordte Cdda Nordtic 4,503 0.7 DBAG VIII DACH 4,136 0.7 Corpfin V DACH 4,136 0.7 Procurtas VI Nordic 3,874 0.7 Procurtas VI Nordic 3,874 0.7 Procurtas VI Nordic 3,874 0.7 Procurtas VI Nordic 3,773 0.6 Chequers Capital XVI France 3,720 0.6 ARX CEE IV France 3,720 0.6 Procurtas Capital XVI France 3,720 0.6 ARX CEE IV Eastern Europe 2,980 0.5 Procurtas Capital XVI France 3,720 0.6 ARX CEE IV Eastern Europe 2,980 0.5 Procurtas Capital XVI Eastern Europe 2,980 0.5 Suma I Capital Fund IV DACH 1,816 0.3 Summa I Capital Fund IV DACH 1,81			5,296	
Montefiore V France 4,303 0.7 DBAG VIII DACH 4.136 0.7 Corpfin V Spain 4.136 0.7 Procuritas VII Nordic 3.874 0.7 Procuritas VII Nordic 3.773 0.6 Chequers Capital XVII France 3.720 0.6 Chequers Capital XVII Eastern Europe 2.980 0.5 Procuritas Capital IV Eastern Europe 2.980 0.5 Procuritas Capital IV Nordic 2.595 0.4 Valaa IV Aurica IV Spain 2.138 0.4 Varika IV Spain 2.388 0.4 3.38 0.3 Surma I Surma I Nordic 1.513 0.3 3.38 0.3 3.38 0.4 3.38 0.4 3.38 0.4 3.38 0.4 3.38 0.4 3.38 0.4 3.39 0.3 3.39 0.3 3.39 0.3 3.39 0.3 3.39 0.3	Capvis III CV		4,710	0.8
DBAG VIII DACH 4,185 0.7 Corpfin V Spain 4,136 0.7 Procuritas VI Nordic 3,874 0.7 Procuritas VI Nordic 3,874 0.7 Procuritas VI Nordic 3,773 0.6 Chequers Capital XVII France 3,720 0.6 ARX CEE IV Eastern Europe 2,980 0.5 Procuritas Capital XVI Nordic 2,517 0.4 talian Portfolio talay 2,517 0.4 Aurica IV Spain 2,138 0.4 Aurica IV Spain 2,138 0.4 Capvis IV Mordic 1,591 0.3 Summa I Spain 1,451 0.2 Summa I Spain 1,451 0.2 Summa I Spain 1,479 0.2 Capvis IVI Spain 1,019 0.2 DAG VIIB DACH 926 0.2 DBAG VIIB DACH 926				0.8
Produritas VII Nordic 3.874 0.7 Produritas VI Nordic 3.720 0.6 Chequers Capital XVII France 3.720 0.6 ARX CEE IV Eastern Europe 2.980 0.5 Procuritas Capital XV Nordic 2.595 0.4 Italian Portfolio Italy 2.517 0.4 Vaaka IV Italy 2.517 0.4 Aurica IV Spain 2.388 0.4 Capvis IV Spain 2.388 0.4 Montefiore IV Spain 2.138 0.4 Summa I Spain 1.513 0.3 Summa I Nordic 1.591 0.3 Summa I Nordic 1.440 0.2 DBAG VIIB DACH 1.014 0.2 DBAG VIIB DACH 956 0.2 DBAG VIIB DACH 922 0.2 DBAG VIIB DACH 922 0.2 DBAG VIIB DACH 920	DBAG VIII			
Procuritas VI Nordic 3,773 0.6 Chequers Capital XVII France 3,770 0.6 ARX CEE IV Eastern Europe 2,980 0.5 Procuritas Capital IV Nordic 2,595 0.4 Italian Portfolio Nordic 2,595 0.4 Vaka IV Finland 2,388 0.4 Aurica IV Spain 2,138 0.4 Capvis IV DACH 1,816 0.3 Montefiore IV DACH 1,816 0.3 Summa I Nordic 1,513 0.3 Summa I Nordic 1,513 0.3 Summa I Nordic 1,490 0.2 Corpfin Capital Fund IV Spain 1,145 0.2 DBAG VIIB DACH 1,019 0.2 DBAG VIIB DACH 9,66 0.2 DBAG VIIB DACH 9,22 0.2 DBAG VIIB DACH 9,20 0.1 PineBridge New Europe II France 3,79 0.1 PineBridge New Europe II France	Corpfin V			
Chequers Capital XVII France 3,720 0.6 ARX CEE IV Eastern Europe 2,980 0.5 Procuritas Capital IV Nordic 2,595 0.4 Italian Portfolio Italy 2,517 0.4 Vaaka IV Eastern Europe 2,980 0.5 Aurica IV Italy 2,517 0.4 Capvis IV Spain 2,138 0.4 Aurica IV Spain 2,138 0.4 Capvis IV DACH 1,816 0.3 Montefiore IV Spain 2,138 0.4 Summa I Nordic 1,591 0.3 Summa I Nordic 1,450 0.2 Corpfin Capital Fund IV Spain 1,145 0.2 Corpfin Capital Fund IV Spain 1,019 0.2 DBAG VIIB DACH 956 0.2 DBAG VIIB DACH 922 0.2 DBAG VIIB DACH 925 - Vaaka II France 357 0.1 Ciclad 5 Eastern Europe 205				
Procuritas Capital IV Nordic 2,595 0.4 Italian Portfolio Italy 2,517 0.4 Italian Portfolio Finland 2,388 0.4 Aurica IV Spain 2,138 0.4 Capvis IV DACH 1.816 0.3 Montefiore IV Spain 2,138 0.4 Summa I Nordic 1,591 0.3 Summa I Nordic 1,490 0.2 Corpfin Capital Fund IV Spain 1,145 0.2 DBAG VIIB DACH 1,019 0.2 Drotobilo Fund III DACH 956 0.2 DBAG VIIB DACH 956 0.2 DAG VIIB DACH 956 0.2 DAG VIII Trance 357 0.1 Vaaka II France 357 0.1 France 357 0.1 PineBridge New	Chequers Capital XVII	France	3,720	0.6
Italian Portfolio Italiy 2,517 0.4 Vaaka IV Finland 2,388 0.4 Varka IV Spain 2,138 0.4 Capvis IV DACH 1,816 0.3 Montefiore IV Prance 1,591 0.3 Summa II Nordic 1,513 0.3 Summa II Orgin Capital Fund IV Spain 1,145 0.2 Corpin Capital Fund IV Spain 1,145 0.2 DBAG VIIB DACH 1,019 0.2 DBAG VIIB DACH 922 0.2 DBAG Fund VI DACH 922 0.2 Chequers Capital XVI DACH 922 0.2 DBAG Fund VI DACH 922 0.2 Chequers Capital XVI DACH 922 0.2 Vaaka II France 629 0.1 Vaaka II France 837 0.1 PineBridge New Europe II Eastern Europe 205 - Montefiore Expansion France 182 - Gilde Buyout Fund III				
Aurica IV Spain 2,138 0.4 Capvis IV DACH 1,816 0.3 Monteficre IV France 1,591 0.3 Summa II Nordic 1,513 0.3 Summa II Nordic 1,490 0.2 Corpfin Capital Fund IV Spain 1,145 0.2 DBAG VIIB DACH 1,007 0.2 DBAG VIIB DACH 1,019 0.2 DBAG VIIB DACH 956 0.2 DBAG Fund VI DACH 956 0.2 Chequers Capital XVI Parace 629 0.1 Vaaka II France 629 0.1 Cickad 5 France 357 0.1 PineBridge New Europe II Eastern Europe 205 - Montefiore Expansion France 182 - Gide Buyout Fund III Benelux 99 - Procurtas Capital V Benelux 99 - Cidat 5 DACH 50 - BaG Fund V DACH 50 -	Italian Portfolio	Italy	2,517	0.4
Capvis IV DÅCH 1.816 0.33 Monteficre IV France 1.591 0.33 Summa I Nordic 1.513 0.3 Corpfin Capital Fund IV Spain 1.145 0.2 DBAG VIIB DACH 1.074 0.2 DBAG VIIB DACH 956 0.2 DBAG VIIB DACH 922 0.2 DBAG VIIB DACH 926 0.2 DBAG VIIB DACH 926 0.2 DBAG VIIB DACH 920 0.2 DBAG VIIB DACH 927 0.2 DBAG VIIB DACH 920 0.2 DAG VI Finand 379 0.1 Vaka II France 357 0.1 PineBridge New Europe II Eastern Europe 205 -				
Montefiore IV France 1,591 0.3 Summa II Nordic 1,513 0.3 Summa II Nordic 1,490 0.2 Corpfin Capital Fund IV Spain 1,149 0.2 DBAG VIIB DACH 1,074 0.2 Portobello Fund III Spain 1,019 0.2 DBAG VIIB DACH 956 0.2 DBAG VIIB DACH 956 0.2 DBAG VIIB DACH 922 0.2 DBAG Fund VI France 629 0.1 Vaaka II France 357 0.1 France 357 0.1 France 182 Vaka II France 182 - Gilde Buyout Fund III Benelux 99 - Procuritas Capital V DACH 50				0.4
Summa I Nordic 1,490 0.2 Corpfin Capital Fund IV Spain 1,145 0.2 DBAG VIIB DACH 1,074 0.2 Portobello Fund III Spain 1,019 0.2 DBAG VIIB Spain 1,019 0.2 DBAG VIIIB DACH 956 0.2 DBAG VIIIB DACH 922 0.2 DBAG VIIIB DACH 922 0.2 DBAG VIIIB DACH 922 0.2 Chequers Capital XVI France 629 0.1 Vaaka II France 357 0.1 Ciclad 5 France 357 0.1 PineBridge New Europe II France 182 - Gilde Buyout Fund III Benelux 99 - Gilde Buyout Fund III Benelux 99 - Gulde Supout Fund III DACH 50 - BAG Fund V DACH 50 -	Montefiore IV	France	1,591	0.3
Corpfin Capital Fund IV Spain 1,145 0.2 DBAG VIIIB DACH 1,074 0.2 DRAG VIIIB Spain 1,019 0.2 DBAG VIIIB DACH 956 0.2 DBAG VIIIB DACH 956 0.2 DBAG Fund VI DACH 922 0.2 Chequers Capital XVI France 629 0.1 Vaaka II France 629 0.1 Ciclad 5 France 357 0.1 PineBridge New Europe II Eastern Europe 205 - Montefiore Expansion France 182 - Procuritas Capital V Benelux 99 - Capvis III DACH 90 - DBAG Fund V DACH 50 -	Summa I Summa I			0.3
Portbello Fund III Spain 1,019 0.2 DBAG VIIIB DACH 956 0.2 DBAG Fund VI DACH 922 0.2 Chequers Capital XVI France 629 0.1 Vaaka II France 379 0.1 Ciclad 5 France 357 0.1 PineBridge New Europe II Eastern Europe 205 - Gilde Buyout Fund III France 182 - Gilde Buyout Fund III Benelux 99 - Capvis III DACH 50 - DBAG Fund V DACH 50 -	Corpfin Capital Fund IV	Spain	1,145	0.2
DBAG VIIIB DâCH 956 0.2 DBAG Fund VI DACH 922 0.2 Chequers Capital XVI Prance 629 0.1 Vaaka II Finland 379 0.1 Ciclad 5 France 357 0.1 PineBridge New Europe II Eastern Europe 205 - Montefiore Expansion France 182 - Gide Buyout Fund III Benelux 99 - Procuritas Capital V Nordic 72 - DBAG Fund V DACH 50 -				0.2
Chequers Capital XVI France 629 0.1 Vaaka II Finland 379 0.1 Ciclad 5 France 357 0.1 PineBridge New Europe II Eastern Europe 205 - Montefiore Expansion France 182 - Gilde Buyout Fund III Benelux 99 - Procuritas Capital V Nordic 72 - DBAG Fund V DACH 50 -	DBAG VIIIB	DACH	956	0.2
Vacka II Finland 379 0.1 Ciclad 5 France 357 0.1 PineBridge New Europe II Eastern Europe 205 - Montefiore Expansion France 182 - Gilde Buyour Fund III Benelux 99 - Procuritas Capital V Nordic 72 - DaGF Fund V DACH 50 -				
PineBridge New Europe II Eastern Europe 205 - Montefiore Expansion France 182 - Gilde Buyout Fund III Benelux 99 - Procuritas Capital V Nordic 72 - Capvis III DACH 50 - DBAG Fund V DACH 5 -	Vaaka II	Finland	379	0.1
Montefiore Expansion France 182 - Gilde Buyout Fund III Benelux 99 - Procuritas Capital V Nordic 72 - Capvis III DACH 50 - DBAG Fund V DACH 5 -	Ciclad 5 BioRridde New Europe II			0.1
Gilde Buyout Fund III Benelux 99 - Procuritas Capital V Nordic 72 - Capvis III DACH 50 - DBAG Fund V DACH 5 -	Montefiore Expansion			-
Capvis III DACH 50 - DBAG Fund V DACH 5 -	Gilde Buyout Fund III	Benelux	99	-
DBAG Fund V DACH 5 -				-
Total Buyout Funds – Continental Europe90,37515.3	DBAG Fund V			-
	Total Buyout Funds – Continental Europe		90,375	15.3

Portfolio Holdings

Private Equity Funds – USA Blue Point Capital IV Purpose Brands (Level 5) Level 5 Fund II Camden Partners IV MidOcean VI Graycliff IV	North America United States		
Camden Partners IV	United States	7,396	1.2
MidOcean VI		3,477	0.6
MidOcean VI	United States	3,433	0.6
	United States	3,129	0.5
Graycliff IV	United States	2,190	0.4
Stellex Capital Partners	North America	2,141	0.4
	North America	1,543	0.3
Blue Point Capital III	North America	1,224	0.2
Gravcliff III	United States	1,032	0.2
TorQuest VI	North America	994	0.2
Blue Point Capital II Total Private Equity Funds - USA	North America	157 26,716	4.6
Private Equity Funds - Global		20,710	4.0
Corsair VI	Global	8,090	1.4
Hg Saturn 3		4,823	0.8
Hg Mercury 4	Global Global	1,244	0.2
PineBridge GEM II	Global	739	0.1
F&C Climate Opportunity Partners	Global	398	0.1
AIF Capital Asia III	Asia	108	-
PineBridge Latin America II	South America	57	_
Warburg Pincus IX	Global	10	
Total Private Equity Funds – Global		15,469	2.6
Venture Capital Funds SEP V	United Kingdom	9,022	1.5
SEP VI	Europe	4,896	0.8
MVM V	Global	4,330	0.7
Kurma Biofund II	Europe	2,768	0.5
MVM VI	Global	1,931	0.3
Northern Gritstone	United Kingdom	1,698	0.3
SEP IV	United Kingdom	946	0.2
Pentech Fund II	United Kingdom	377	0.1
SEP III	United Kingdom	59	
Environmental Technologies Fund	Europe	57	-
Life Sciences Partners III	Western Europe	31	_
SEP II	United Kingdom	4	
Total Venture Capital Funds	5	26,119	4.4
Secondary Funds The Aurora Fund	Europe	193	
Total Secondary Funds	Europe	193	
Direct Investments/Co-Investments			
Weird Fish	United Kingdom	14,845	2.5
Sigma	United States	12,521	2.1
TWMA	United Kingdom DACH	12,087	2.1
Utimaco	Italy	10,791	1.8
San Siro		10,588	1.8
Aurora Payment Solutions	United States	9,699	1.6
Amethyst Radiotherapy	Europe	9,204	1.6
Breeze Group (CAS)	United Kingdom	8,020	1.4
Cyclomedia	Netherlands	7,958	1.4
CARDO Group	United Kingdom	7,185	1.2
Asbury Carbons	North America	7,124	1.2
Velos IoT (JT IoT)	United Kingdom	6,853	1.2
Prollenium	North America	6,689	1.1
Swanton	United Kingdom	6,611	1.1
Habitus	Denmark	6,473	1.1
Orbis	United Kingdom	6,282	1.1
Family First	United Kingdom	6,178	1.1
Cyberhawk	United Kingdom	5,996	1.0
Polaris Software (StarTraq)	United Kingdom	5,806	1.0
Rosa Mexicano	United States	5,449	0.9
Cybit (Perfect Image)	United Kingdom	4,874	0.8
MedSpa Partners	Canada	4,805	0.8
123Dentist	Canada	4,729	0.8
Braincube	France	4,652	0.8
LeadVenture	United States	4,412	0.8
1Med	Switzerland	4,163	0.7
AccuVein	United States	4,146	0.7
Walkers Transport	United Kingdom	4,127	0.7
Dotmatics	United Kingdom	3,934	0.7
PathFactory	Canada	3,544	0.6
Collingwood Insurance Group	United Kingdom	3,452	0.6
Vero Biotech	United States	3,266	0.6
GT Medical	United States	3,209	0.5
Educa Edtech	Spain	3,072	0.5
AccountsIQ	Ireland	2,462	0.4
Neurolens	United States	2,266	0.4
OneTouch	United Kingdom	2,122	0.4
Omlet	United Kingdom	2,039	0.3
Alessa (Tier1 CRM)	Canada	2,022	0.3
Agilico (DMC Canotec)	United Kingdom	1,734	0.3
Frendy	Finland	1,716	0.3
Bomaki	Italy	1,516	0.3
Rephine	United Kingdom	1,289	0.2
Avalon	United Kingdom	1,234	0.2
Ambio Holdings	United States	1,175	
Jollyes	United Kingdom	786	0.1
Leader96	Bulgaria	732	0.1
TDR Algeco/Scotsman	Europe	277	
Total Direct Investments/Co-investments	· · · · ·	244,114	41.4
Total Portfolio		589,677	100.0

Statement of Comprehensive Income

	Three months ended 31 March 2025 (unaudited)			Three months ended 31 March 2024 (unaudited)			Year ended 31 December 2024 (audited)		
	Revenue £'000	Capital £'000	Total £'000	Revenue £'000	Capital £'000	Total £'000	Revenue £'000	Capital £'000	Total £'000
Income									
(Losses)/gains on investments held at fair value	-	(548)	(548)	-	(5,683)	(5,683)	-	25,144	25,144
Exchange (losses)/gains	-	(1,151)	(1,151)	-	1,368	1,368	-	5,055	5,055
Investment income	810	-	810	570	-	570	3,270	-	3,270
Other income	108	-	108	180	-	180	961	-	961
Total income	918	(1,699)	(781)	750	(4,315)	(3,565)	4,231	30,199	34,430
Expenditure									
Investment management fee – basic fee Investment management fee – performance fee	(123)	(1,103)	(1,226)	(122)	(1,099)	(1,221)	(489)	(4,404)	(4,893)
Other expenses	(300)	-	(300)	(334)	-	(334)	(1,226)	-	(1,226)
Total expenditure	(423)	(1,103)	(1,526)	(456)	(1,099)	(1,555)	(1,715)	(4,404)	(6,119)
Profit/(loss) before finance costs and taxatior	n 495	(2,802)	(2,307)	294	(5,414)	(5,120)	2,516	25,795	28,311
Finance costs	(171)	(1,536)	(1,707)	(218)	(1,965)	(2,183)	(864)	(7,778)	(8,642)
Profit/(loss) before taxation	324	(4,338)	(4,014)	76	(7,379)	(7,303)	1,652	18,017	19,669
Taxation	-	-	-	-	-	-	-	-	-
Profit/(loss) for period/total					(= 0 = 0)	(7.000)	4 070	10.047	10.000
comprehensive income	324	(4,338)	(4,014)	76	(7,379)	(7,303)	1,652	18,017	19,669
Return per Ordinary Share	0.45p	(6.06)p	5.61p	0.10p	(10.14)p	(10.04)p	2.30p	25.08p	27.38p

Amounts Recognised as Dividends

	e months ended 31 March 2025 (unaudited) £'000	(unaudited)	Year ended 31 December 2024 (audited) £'000
Quarterly Ordinary Share dividend of 7.01p per share for the quarter ended 30 September 2023	_	5,100	5,100
Quarterly Ordinary Share dividend of 7.01p per share for the quarter ended 31 December 2023	-	-	5,030
Quarterly Ordinary Share dividend of 7.01p per share for the quarter ended 31 March 2024	-	-	5,012
Quarterly Ordinary Share dividend of 7.01p per share for the quarter ended 30 June 2024	-	-	5,012
Quarterly Ordinary Share dividend of 7.01p per share for the quarter ended 30 September 2024	5,012	-	-
	5,012	5,100	20,154

The above table does not form part of the Statement of Comprehensive Income.

Balance Sheet

	As at 31 March 2025 (unaudited) £'000	As at 31 March 2024 (unaudited) £'000	As at 31 December 2024 (audited) £'000
Non-current assets			
Investments at fair value through profit or loss	589,677	607,796	584,097
Current assets			
Other receivables	841	3,115	1,110
Cash and cash equivalents	7,836	16,534	16,000
	8,677	19,649	17,110
Current liabilities			
Other payables	(4,324)	(13,129)	(3,859)
Interest-bearing bank loan	-	(65,746)	-
	(4,324)	(78,875)	(3,859)
Net current assets/(liabilities)	4,353	(59,226)	13,251
Total assets less current liabilities	594,030	548,570	597,348
Non-current liabilities			
Interest-bearing bank loan	(98,227)	(49,880)	(92,519)
Net assets	495,803	498,690	504,829
Equity			
Called-up ordinary share capital	739	739	739
Share premium account	2,527	2,527	2,527
Special distributable capital reserve	3,818	9,597	3,818
Special distributable revenue reserve	31,403	31,403	31,403
Capital redemption reserve	1,335	1,335	1,335
Capital reserve	455,981	453,089	465,007
Shareholders' funds	495,803	498,690	504,829
Net asset value per Ordinary Share	693.40p	685.46p	706.03p

Reconciliation of Movements in Shareholders' Funds

	Three months ended 31 March 2025 (unaudited) £'000	31 March 2024	Year ended 31 December 2024 (audited) £'000
Opening shareholders' funds	504,829	511,093	511,093
Buyback of ordinary shares	-	-	(5,779)
(Loss)/profit for the period/total comprehensive income	(4,014)	(7,303)	19,669
Dividends paid	(5,012)	(5,100)	(20,154)
Closing shareholders' funds	495,803	498,690	504,829

Notes to the Accounts

1 The unaudited quarterly results have been prepared on the basis of the accounting policies set out in the statutory accounts of the Company for the year ended 31 December 2024. Earnings for the three months to 31 March 2025 should not be taken as a guide to the results for the year to 31 December 2025.

2 Investment management fee

	Three months ended 31 March 2025 (unaudited)			Three months ended 31 March 2024 (unaudited)			Year ended 31 December 2024 (audited)		
	Revenue £'000	Capital £'000	Total £'000	Revenue £'000	Capital £'000	Total £'000	Revenue £'000	Capital £'000	Total £'000
Investment management fee – basic fee	123	1,103	1,226	122	1,099	1,221	489	4,404	4,893
Investment management fee – performance fee	- 123	1,103	- 1,226	122	1,099	- 1,221	489	- 4,404	4,893

3 Finance costs

	Three months ended			Three months ended			Year ended			
	31 March 2025				31 March 2024			31 December 2024		
		(unaudited)			(unaudited)			(audited)		
	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total	
	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	
Interest payable on bank loans	171	1,536	1,707	218	1,965	2,183	864	7,778	8,642	

4 Returns and net asset values

	Three months ended 31 March 2025 (unaudited)	Three months ended 31 March 2024 (unaudited)	Year ended 31 December 2024 (audited)
The returns and net asset values per share are based on the following figures:			
Revenue return	£324,000	£76,000	£1,652,000
Capital return	(£4,338,000)	(£7,379,000)	£18,017,000
Net assets attributable to shareholders	£495,803,000	£498,690,000	£504,829,000
Number of shares in issue at end of period	71,502,938	72,752,938	71,502,938
Weighted average number of shares in issue during period	71,502,938	72,752,938	71,845,834

5 The financial information for the three months ended 31 March 2025, which has not been audited or reviewed by the Company's auditor, comprises non-statutory accounts within the meaning of Section 434 of the Companies Act 2006. Statutory accounts for the year ended 31 December 2024, on which the auditor issued an unqualified report, will be lodged shortly with the Registrar of Companies. The quarterly report is available on the Company's website www.ctprivateequitytrust.com.

Corporate Information

Directors

Richard Gray (Chairman)* Craig Armour† Audrey Baxter Tom Burnet Swantje Conrad

Company Secretary

Columbia Threadneedle AM (Holdings) PLC Quartermile 4 7a Nightingale Way Edinburgh EH3 9EG Tel: 0131 573 8300

Alternative Investment Fund Manager ('AIFM') and Investment Manager

Columbia Threadneedle Investment Business Limited Quartermile 4 7a Nightingale Way Edinburgh EH3 9EG Tel: 0131 573 8300

Auditor

BDO LLP 55 Baker Street London W1U 7EU

Broker and Financial Adviser

Singer Capital Markets 1 Bartholomew Lane London EC2N 2AX

Solicitors

CMS Cameron McKenna LLP Saltire Court 20 Castle Terrace Edinburgh EH1 2EN

Depositary

JPMorgan Europe Limited 25 Bank Street Canary Wharf London E14 5JP

Bankers

JPMorgan Chase Bank 25 Bank Street Canary Wharf London E14 5JP

The Royal Bank of Scotland International Limited 1 Princes Street London EC2R 8BP

Company Number

Registered in Scotland No: SC179412

* Chairman of the Management Engagement Committee and the Nomination Committee

† Chairman of the Audit Committee with effect from 29 May 2025









CT Private Equity Trust PLC

Quarterly Report 31 March 2025

Registered office:

Quartermile 4 7a Nightingale Way Edinburgh EH3 9EG

₲ 0131 573 8300

Registrars:

- MUFG Corporate Markets
 Central Square
 29 Wellington Street
 Leeds LS1 4DL
- ₲ 0371 664 0300*
- www.mpms.mufg.com

* Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales.



To find out more visit **columbiathreadneedle.com**

© 2025 Columbia Threadneedle Investments. Columbia Threadneedle Investments is the global brand name of the Columbia and Threadneedle group of companies.